The primary therapeutic role of Cleating (Diflunisal), a nonsteroidal anti-inflammatory drug (NSAID), plays a role in managing symptoms related to physical discomfort and the manifestations of inflammation. It is commonly applied in situations involving acute or long-term symptom management where patients experience distressing symptoms.

Cleating is commonly used across conditions characterized by periods of heightened symptoms, such as Rheumatoid Arthritis and Osteoarthritis, as well as for managing acute episodes like sprains, strains, and pain following dental extractions. It is used to address the symptom clusters of joint pain, swelling, and stiffness. By being relevant for easing inflammation and physical discomfort, it contributes to improved comfort during symptomatic periods.

“It is commonly applied in scenarios where additional management of discomfort is required, offering symptomatic relief that helps patients cope more steadily.”

The medication is also applied in specific therapeutic areas where additional management of discomfort is needed, such as in certain conditions involving functional stress.

Quick Fact: Relevant for Easing Joint Pain

Regulatory References

1. NIH DailyMed overview

The eligibility for using Cleating (Diflunisal) is strictly defined by regulatory contraindications and population restrictions.

Who Must Not Use (Contraindicated)

Use is absolutely contraindicated in patients with a known hypersensitivity to Diflunisal or a history of allergic-type reactions (such as asthma or urticaria) after taking aspirin or other NSAIDs.

The medicine is also prohibited for:

• Treatment of peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery.
• Individuals with active gastrointestinal bleeding or peptic ulcer disease.
• Pregnant women starting at 30 weeks gestation (the third trimester).
• Patients with severe renal impairment or severe hepatic impairment.
• Patients with severe, uncontrolled heart failure.

Eligibility Restrictions and Caution

• Age: Safety and effectiveness have not been established in children under 12 years of age, and use is not recommended. Older adults (65+) may use the medicine but require caution due to a higher risk of adverse events.
• Pregnancy and Lactation: Use is not recommended during the first and second trimesters of pregnancy or while breastfeeding.

Interactions with other medicines and products

Contraindications and Major Restrictions

The co-administration of Cleating (Diflunisal) with Aspirin or other Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) is not recommended and is officially contraindicated in patients with a history of sensitivity reactions, such as asthma or hives, precipitated by these agents. Combining this product with Ketorolac is also advised against in regulatory labeling.

Exposure-Modifying Interactions (Pharmacokinetic Effects)

The regulatory profile documents several interactions that alter drug exposure. Concomitant use with Probenecid causes a substantial decrease in the clearance of Diflunisal, leading to significantly increased plasma concentrations of the active ingredient. Diflunisal is also documented to increase the plasma levels of co-administered Acetaminophen, Indomethacin, and the diuretic Hydrochlorothiazide. Conversely, the continuous use of certain Antacids may reduce the absorption and plasma levels of Diflunisal.

Pharmacodynamic Risk Enhancement and Constraints

When combined with Anticoagulants, there is an increased risk of bleeding and hemorrhage due to an additive effect on platelet function. Diflunisal may also potentiate the hypoglycemic effect of oral hypoglycemic agents. Furthermore, co-administration with Alcohol increases the risk of serious gastrointestinal adverse events. A timing separation rule is specified for Antacids to mitigate the interaction that reduces Diflunisal absorption. Additionally, the risk of deterioration of renal function is noted when co-administering with ACE Inhibitors or ARBs, particularly in individuals with compromised renal reserve.

Inhibition of the Prostaglandin Synthesis Pathway

This mechanism involves the non-selective inhibition of the Cyclooxygenase (COX) enzymes, both the constitutive COX-1 and the inducible COX-2 isoforms. By blocking these enzymes, the drug prevents the conversion of arachidonic acid into prostaglandins, which are key chemical mediators. This action constrains the generation of eicosanoids that modulate vascular permeability and afferent nerve firing thresholds.

---

Dual Action on Inflammatory Signals

Beyond its primary enzymatic inhibition, the drug engages secondary mechanisms by directly binding to and neutralizing key inflammatory signaling proteins like High-Mobility Group Box 1 (HMGB1). This interference with non-COX pathways, which includes modulating Histone Acetyltransferases, influences the molecular sequence governing inflammatory cell migration and sustained tissue response.

---

Constraint on Central Mechanisms

The drug is highly protein-bound and possesses poor lipophilicity, which significantly restricts its transport across the blood-brain barrier (BBB). This constraint limits the drug's access to central targets in the brain and cerebrospinal fluid, restricting its sphere of physiological action predominantly to the peripheral nervous system. Consequently, the mechanism lacks the required engagement with central prostaglandin synthesis to modulate the hypothalamic thermoregulatory set-point.

Official Administration Guidelines for Cleating (Diflunisal)

The usage of Cleating is standardized, focusing on the oral administration of 250 mg and 500 mg tablets. The medication is intended for use at the lowest effective dose for the shortest possible duration.

Administration Scope	Guideline
Route of administration	Oral administration only. The tablets must be swallowed whole and should not be crushed or chewed.
Timing in relation to meals	Administration is often recommended with food, milk, or water to help mitigate potential gastrointestinal discomfort.

---

Standard Labeled Dosing Regimens

Dosing regimens are precisely detailed for both acute and chronic use. The total daily intake must not exceed 1500 mg.

Dosing Context	Dosing Schedule
For Acute Pain Relief	An initial (loading) dose of 1000 mg is typically used once, followed by a maintenance dose of 500 mg every 12 hours, or adjusted to 250 mg or 500 mg every 8 to 12 hours.
For Chronic Conditions	Doses for chronic inflammatory conditions typically range from 500 mg to 1000 mg daily, administered in two divided doses.

---

Procedural and Population Constraints

Official protocols include specific requirements for certain patient populations and administration conditions.

• Renal Impairment: A mandatory 50% dose reduction of the standard amount is required when creatinine clearance (CrCl) is less than 50 mL/min.
• Geriatric Use: Dosage should be selected with caution, often initiating at a lower dose due to age-related physiological changes.
• Pediatric Use: Safety and efficacy have not been established for children younger than 12 years of age.

The use protocol specifies that doses should be taken at approximately the same times every day to maintain steady plasma concentrations.

Evidence for Use in Acute Pain and Inflammation

Research involves short-term, randomized, controlled trials (RCTs) and meta-analyses to explore how symptoms change over time. These studies monitor responses over brief intervals, typically 4 to 12 hours, using standardized scales to measure pain intensity and document the use of rescue medication. Findings describe patterns observed in these studies compared to a placebo or other comparators. The results apply only to the studied populations during the specified short time frame, as there is limited information when this medicine is evaluated for persistent acute pain.

---

Evidence for Use in Chronic Joint Conditions

For conditions like Rheumatoid Arthritis and Osteoarthritis, Cleating was evaluated in controlled trials lasting a few months. Research describes studies that monitored patient-reported outcomes such as tender and swollen joints, and the reported duration of morning stiffness. Studies report how symptoms were measured and documented in the observed populations when compared against other pharmaceutical comparators. Comparative evidence is lacking regarding the long-term outcomes related to joint structure or disease progression.

---

Evidence for Use in Transthyretin Amyloidosis

Cleating was observed in research for Transthyretin Amyloidosis ( ATTR), a complex condition affecting nerves and the heart. For ATTR polyneuropathy, studies included a long-term, randomized, controlled trial. Research describes patterns observed related to the measurement of nerve-related symptoms over a two-year period. However, for cardiac ATTR, evidence is mainly derived from observational settings, which suggests the certainty remains low because robust, placebo-controlled RCTs have not been conducted.

---

Research Gaps and Limitations

Most primary research has focused on adult populations, meaning data for certain groups, especially children and adolescents, remain insufficient. Furthermore, the reliance on retrospective and non-randomized data in some complex indications, along with the exclusion of patients with very advanced stages of disease, limits the generalizability of findings. Research provides context but not individual predictions.

Key Studies & References

1. DIFLUNISAL tablet - Official Drug Label Information

Common questions about Cleating (FAQ)

---

Q: What happens if I miss a dose of Cleating?

Official patient information describes that the procedure for a missed dose is to take it as soon as it is remembered. However, if it is already close to the time for the next scheduled dose, the procedure is to skip the missed dose and continue the regular schedule. It is advised not to take a double dose to compensate for the one that was missed.

---

Q: What foods or drinks should people avoid while taking Cleating?

Regulatory documents advise that co-administration with alcohol increases the risk of serious gastrointestinal adverse events, such as bleeding. Administration is officially described as being frequently recommended with food, milk, or water, a strategy intended to help mitigate potential gastrointestinal discomfort.

---

Q: Is Cleating safe to take with common pain relievers like ibuprofen?

Official labeling states that co-administration with other Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), which includes medicines like ibuprofen, is not recommended. Combining these products is documented to increase the overall risk of gastrointestinal adverse events, such as bleeding and ulceration.

---

Q: Is it normal to feel a little dizzy when first starting Cleating?

Yes, official documents list dizziness as a common possible side effect associated with the use of this medicine, affecting the nervous system. The occurrence of dizziness is documented as part of the known safety profile.

---

Q: Is it possible to take Cleating with common vitamins or minerals?

Regulatory documents note a specific interaction with certain Antacids—a mineral-based product—where continuous use may reduce the medicine's absorption and plasma levels. Official guidance specifies that a time separation rule is to be observed to mitigate this interaction.

---

Q: How long can a person typically stay on Cleating?

This medicine is indicated for both short-term acute use and the longer-term management of chronic conditions, so the duration varies by the condition being treated. However, official safety documentation emphasizes that the risk of serious cardiovascular thrombotic events (like heart attack or stroke) and gastrointestinal adverse events is documented to increase with the duration of use.

---

Q: Is it true that Cleating needs to be taken with food?

Administration is recommended to be taken with food, milk, or water to help mitigate potential gastrointestinal discomfort. This approach is described as a recommendation for improving tolerability, and is not formally mandated for systemic absorption.

---

Q: How quickly does Cleating usually start working?

Clinical information found in drug monographs describes that the medicine typically has an onset time of approximately 1 hour. The maximum pain relief effect is generally seen within 2 to 3 hours after administration.

---

Q: Is there a generic version of Cleating available?

Yes, the medicine is available in generic form. The active ingredient is Diflunisal, and generic oral tablets are currently available. The original brand name product was previously known as Dolobid.

---

Q: Does Cleating have a risk of dependence or addiction?

Official classification describes this medicine as a non-opioid, non-narcotic analgesic. This classification indicates that the medicine does not carry the risk of dependence or addiction associated with narcotic drug classes.

---

Q: What are the long-term effects of taking Cleating?

The primary long-term concerns documented in regulatory information relate to the risk of serious side effects that increase over time. These include an increased risk of serious cardiovascular thrombotic events (such as heart attack or stroke) and serious gastrointestinal adverse events (such as bleeding or ulceration).

---

Q: Can Cleating be taken by people with kidney problems?

Use in people with kidney problems requires caution. Official protocols require a mandatory 50% dose reduction when renal function is reduced. Furthermore, the medicine is formally contraindicated (prohibited) in patients with advanced renal disease.

---

Q: What is the meaning of the [Technical Term in Research] often mentioned with Cleating?

Terms like prostaglandins refer to the chemical mediators in the body responsible for inflammation and pain. Cleating is documented to function by interrupting the bodily mechanism that generates these mediators.

---

Q: Do many people experience a rash while on Cleating?

Official drug monographs note that skin reactions such as hives, itching, or a general skin rash can occur. Additionally, regulatory documents warn that rare but severe skin reactions, such as Stevens-Johnson Syndrome (SJS), have been reported.

---

Q: Can Cleating be used by teenagers?

The medicine's safety and effectiveness have not been established in children younger than 12 years of age, and its use is not recommended for that group. For teenagers (12 years and older), official information advises caution, particularly if they have a viral illness like chickenpox or the flu, due to a potential risk of Reye's syndrome.

---

Q: Are there different strengths or formulations of Cleating?

Official administration guidelines detail that the medicine is standardized for use as an oral tablet and is available in common strengths of 250 mg and 500 mg.

---

Q: Is it better to take Cleating in the morning or at night?

Official use protocols specify that doses should be taken at approximately the same times every day to maintain steady concentrations in the body. The precise timing is part of the established patient dosing regimen.

---

Q: Can Cleating be used by people who are actively trying to conceive?

Regulatory documents note that Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) may have the potential to impair female fertility. Regulatory documents state that consideration should be given to the withdrawal of the medicine in women who are having difficulty conceiving or are undergoing infertility investigation.

---

Q: Does Cleating interact with blood pressure medication?

Yes, official documents specify that co-administration with specific types of blood pressure medications, such as ACE Inhibitors and ARBs, is documented. This combination is noted to increase the risk of deterioration of renal function, particularly in those with pre-existing kidney issues.

---

Q: What is the general difference between Cleating and other medications in its class?

Cleating (Diflunisal) is officially classified as an NSAID and a salicylate derivative. It is noted for its long plasma half-life which allows for sustained effects. Furthermore, it has a documented dual action mechanism involving both the COX pathway and the HMGB1 inflammatory pathway.

---

Q: Is Cleating considered a 'strong' medicine?

Official regulatory documents state the purpose of the medicine is to relieve mild to moderate pain and reduce tissue swelling. This labeled indication helps to define the scope of its analgesic action.

---

Q: Is Cleating meant to be taken every day?

The medicine can be prescribed for use in different durations. Dosing regimens are detailed for both short-term acute pain relief and for longer-term management of chronic conditions; the frequency of use is determined by the specific condition being treated.

How to Store and Dispose of Cleating (Diflunisal)

Official labeling mandates specific conditions for storing Cleating oral tablets to maintain stability. The medication must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). Storage must always occur in a tightly closed container to protect the tablets from excessive moisture and humidity. It is mandatory to keep Cleating out of the sight and reach of children to prevent accidental ingestion.

Disposal Requirements

Expired or unused Cleating must be disposed of according to official regulatory guidelines. Disposal via a drug take-back program is the recommended method. If a take-back program is unavailable, tablets should be prepared for household trash by mixing them with an unappealing substance, sealing the mixture in a plastic bag, and then discarding it. Do not flush Cleating down a toilet or pour it down a drain.